NEWAMSTERDAM PHARMA CO NV (NAMS) Stock Earnings & Estimates
USA - NASDAQ:NAMS - NL00150012L7 - Common Stock
38.58 USD
+0.02 (+0.05%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 97.5M | 13.254M -86.41% | 32.622M 146.13% | 32.263M -1.10% | 18.221M -43.52% | 149.31M 719.44% | 397.16M 166.00% | 755.49M 90.22% | 1.12B 48.25% | 1.321B 17.95% | 1.573B 19.08% | |||
| EBITDA YoY % growth | -126.7K | -1.352M -967.32% | -3.867M -185.96% | -218.688M -5,555.24% | -192.78M 11.85% | -226.496M -17.49% | -159.504M 29.58% | 12.049M 107.55% | 691.88M 5,642.22% | 1.354B 95.70% | 1.577B 16.47% | N/A | N/A | |
| EBIT YoY % growth | -127.7K | -1.366M -969.93% | -3.939M -188.30% | -192.371M -4,783.75% | -190.345M 1.05% | -221.43M -16.33% | -244.193M -10.28% | -179.004M 26.70% | -3.94M 97.80% | 300.58M 7,728.23% | 623.54M 107.45% | 770.9M 23.63% | 927.68M 20.34% | |
| Operating Margin | N/A | N/A | -4.04% | -1,451.42% | -583.49% | -686.33% | -1,340.17% | -119.89% | -0.99% | 39.79% | 55.67% | 58.36% | 58.98% | |
| EPS YoY % growth | N/A | N/A | N/A | -2.21 -1,306.89% | -2.12 -16.91% | -1.39 46.24% | -1.88 -35.66% | -1.68 10.83% | -0.30 82.32% | 1.79 704.44% | 3.59 100.04% | 4.02 12.21% | 5.18 28.76% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.44 53.05% | -0.45 -33.65% | -0.50 -232.23% | -0.49 19.87% | -0.51 -17.03% | -0.49 -7.74% | -0.57 -14.62% | -0.52 -6.43% | -0.47 8.18% |
| Revenue Q2Q % growth | 5.127M -59.86% | -100.00% | -100.00% | -100.00% | 297.84K -94.19% | 734.4K | 1.112M | 7.477M | 13.474M 4,423.91% |
| EBITDA Q2Q % growth | -51.215M | -80.233M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -57.434M -5.78% | -66.891M -15.12% | -69.823M -7.04% | -64.297M -20.58% | -68.299M -18.92% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | -0.61 -238.89% | -0.40 | -0.21 | -50.97% |
| Q2 2025 Q2Q % growth | -0.15 63.41% | -0.50 | 0.35 | 70.09% |
| Q1 2025 Q2Q % growth | -0.34 67.92% | -0.50 | 0.16 | 31.66% |
| Q4 2024 Q2Q % growth | -0.93 -60.07% | -0.50 | -0.43 | -87.61% |
| Q3 2024 Q2Q % growth | -0.18 67.54% | -0.51 | 0.33 | 64.67% |
| Q2 2024 Q2Q % growth | -0.41 11.09% | -0.59 | 0.18 | 30.32% |
| Q1 2024 Q2Q % growth | -1.06 -142.72% | -0.54 | -0.52 | -97.14% |
| Q4 2023 Q2Q % growth | -0.58 -18.67% | -0.61 | 0.03 | 4.67% |
| Q3 2023 Q2Q % growth | -0.55 9.31% | -0.50 | -0.06 | -11.52% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 348K -98.80% | 5.392M | -5.044M | -93.55% |
| Q2 2025 Q2Q % growth | 19.145M 740.06% | 1.63M | 17.515M | 1,074.54% |
| Q1 2025 Q2Q % growth | 2.978M 112.56% | 1.607M | 1.371M | 85.31% |
| Q4 2024 Q2Q % growth | 12.772M 1,521.66% | 1.791M | 10.981M | 613.12% |
| Q3 2024 Q2Q % growth | 29.111M 877.73% | 1.91M | 27.201M | 1,424.14% |
| Q2 2024 Q2Q % growth | 2.279M -76.17% | 1.406M | 873K | 62.09% |
| Q1 2024 Q2Q % growth | 1.401M -49.86% | 1.778M | -377K | -21.20% |
| Q4 2023 Q2Q % growth | 787.59K -99.19% | 1.998M | -1.21M | -60.58% |
| Q3 2023 Q2Q % growth | 2.977M | 2.291M | 686.42K | 29.96% |
| Q2 2023 Q2Q % growth | 9.562M | 2.794M | 6.768M | 242.23% |
| Q4 2022 Q2Q % growth | 97.5M | 3.807M | 93.693M | 2,461.07% |
| Q3 2022 Q2Q % growth | 1.785M | -1.785M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | -16.39% |
| Revenue | 0% | 0% | 0% | 86.41% |